Sandoz Gains Biosimilar Approval

Sandoz (Holzkirchen, Germany), a division of Novartis, says it has received marketing authorization for the first ever biosimilar to be sold in Japan. Approval of the product, recombinant human growth hormone somatropin, paves the way for greater market access for high-quality biopharmaceuticals in Japan, Sandoz says. Japan is the second-largest pharmaceuticals market after the U.S. Biosimilars are approved versions of innovator biopharmaceutical products, following patent expiry. The Sandoz product is approved for the treatment of growth hormone deficiency in...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers